Delcath Systems Inc (DCTH)

[errett]

11. BENEFIT AND RISK SUMMARY-----In the randomized, controlled Phase 3 study, melphalan/PHP treatment resulted in a clinically meaningful and highly statistically significant improvement in hPFS. The safety profile of melphalan/PHP treatment is well characterized and thus, toxicities can be addressed by a combination of patient selection criteria, patient monitoring and appropriate intervention, and dose modification and timing of the next treatment cycle. There are no approved therapies or a standard of care for patients with metastatic, ocular melanoma in the liver that is unresectable.
Thus, there is a clear unmet medical need and melphalan/PHP treatment provides a new treatment option for these patients.

This sounds very positive to me.